Trial Profile
A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn's disease in remission. [Studio, multicentrico di fase II, di estensione a lungo termine, randomizzato, in doppio cieco, controllato vs placebo per valutare la sicurezza e la tollerabilita' di GED-0301 40 mg, per il mantenimento della remissione del Morbo di Crohn] [EXTENSION OF 700213839]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2013
Price :
$35
*
At a glance
- Drugs Mongersen (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms IGON-2
- 20 Mar 2013 New trial record